Clinical trials: Hepatocellular Carcinoma Recurrent
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Advanced Adult Primary Liver Cancer, Liver Metastases
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or cancer that has spread to the liver…
- Conditions
- Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02119065
- Testing
- positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Cincinnati
Extrahepatic Bile Duct Cancer, Liver Cancer
Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030511
- Testing
- fluorouracil, conventional surgery, radiation therapy
- Where
- 6 sites in United States, Belgium and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hepatocellular Carcinoma, Liver Transplant; Complications
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
The use of devices for liver grafts perfusion before transplantation, either hypothermic (HOPE) or normothermic (NMP), is rapidly spreading thanks to the promising results obtained so far in terms of graft survival and…
- Trial name
- NCT06236568
- Testing
- D-HOPE machine perfusion, Liver transplantation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00047346
- Testing
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
HCC
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients with Hepatocellular Carcinoma at Risk of Recurrence after Surgical Resection.
- Trial name
- NCT06560827
- Testing
- CT011 CAR-GPC3 T Cells Injection
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Hepatocellular Carcinoma
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Trial name
- NCT01570166
- Testing
- HR, RFA
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-sen University
Recurrent Hepatocellular Carcinoma
Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma
This study is aiming to evaluate the clinical efficacy of complete laparoscopic resection of recurrent hepatocellular carcinoma (HCC).
- Trial name
- NCT02613156
- Testing
- laparoscopic resection
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Recurrent
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival.
- Trial name
- TARGET-HCC (NCT07118202)
- Testing
- TheraBionic P1
- Where
- 6 sites in United States
- Volunteers
- 198 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib ditosylate works in treating patients with unresectable liver or…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00107536
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Metastatic Cancer
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
RATIONALE: Heating tumors to several degrees above body temperature may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of heat therapy in treating patients who have unresectable primary or metastatic liver…
- Trial name
- NCT00004136
- Testing
- Radiofrequency Ablation
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocarcinoma
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation
- Trial name
- NCT03356236
- Where
- 17 sites in China
- Volunteers
- 828 people
- Sponsor
- Yue Han
Hepatocellular Carcinoma (HCC) Prognosis, Contrast-enhanced Ultrasound
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases.
- Trial name
- NCT07600346
- Testing
- Contrast-Enhanced Ultrasound
- Volunteers
- 105 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma, Microwave Ablation
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer, Lenvatinib
- Trial name
- NCT05444478
- Testing
- Microwave ablation, Lenvatinib
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Sun Yat-sen University
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Liver Transplantation, Adjuvant FOLFOX Plus Lenvatinib
Stratification for F-L Therapy After LT
Objective: To stratify recipients who underwent adjuvant FOLFOX plus lenvatinib (F-L) therapy following liver transplantation (LT) for hepatocellular carcinoma and provide guidance for clinical adjuvant therapy.
- Conditions
- Liver Transplantation, Adjuvant FOLFOX Plus Lenvatinib, Machine Learning
- Trial name
- NCT06564103
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xiao Xu
Child-Pugh Class A, Child-Pugh Class B
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer…
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT02762266
- Testing
- Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent
- Where
- 2 sites in United States, Japan
- Volunteers
- 13 people
- Sponsor
- Stanford University
Hepatocellular Carcinoma, Recurrence
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
This prospective multicenter non-randomized controlled study evaluates the efficacy and safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with microvascular invasion after radical resection…
- Trial name
- NCT02867280
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
Recurrent Hepatocellular Carcinoma, Lenvatinib
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage.
- Conditions
- Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy, Ablation
- Trial name
- NCT06609850
- Testing
- TACE, Ablation, Lenvatinb
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University